2 In separate clinical studies of adults with overweight or obesity, about 1 in 4 taking Wegovy oral semaglutide 25 mg (64 weeks), about 1 in 3 taking Wegovy injection 2.4 mg (68 weeks), and about 1 in 2 taking Wegovy injection 7.2 mg (72 weeks) lost 20% of body weight, alongside diet and exercise
This is why protein and exercise are considered essential rather than optional components of treatment
So there is a little bit of concern about that. Its a concern that has been pervasive enough for existing drugs that Lilly released a commercial ahead of the 2024 Oscars urging against vanity use
View Product Why Retatrutide Causes Fatigue: The Science Explained Energy Timeline: What to Expect Each Month Strategy 1: Managing the Caloric Deficit Problem Strategy 2: Protein Timing for Sustained Energy Strategy 3: The Electrolyte Fix Most People Miss Strategy 4: Stabilizing Blood Sugar Throughout the Day Strategy 5: B12 and Iron Optimization Strategy 6: Sleep Quality Improvements That Work Strategy 7: Hydration Beyond Just Water Strategy 8: Exercise That Boosts Rather Than Drains Strategy 9: Smart Caffeine Management Strategy 10: Meal Timing Optimization Strategy 11: Supplements That Actually Help Strategy 12: Addressing Mental Fatigue and Brain Fog Strategy 13: When Dose Adjustment Makes Sense Strategy 14: Thyroid Function Monitoring Strategy 15: Muscle Preservation for Energy Strategy 16: Stress and Cortisol Management Strategy 17: Weekly Energy Management Schedule Strategy 18: Warning Signs That Need Medical Attention Frequently Asked Questions Glossary of Terms References Why Retatrutide Causes Fatigue: The Science Explained Understanding why fatigue happens during Retatrutide treatment helps you address the root causes rather than just masking symptoms
Details of ongoing phase 3 studies can be found on ClinicalTrials.gov
GLP-1 drugs are generally contraindicated Personal or family history of medullary thyroid cancer (MTC): GLP-1 drugs carry a boxed warning for thyroid C-cell tumors in rodent studies Multiple Endocrine Neoplasia syndrome type 2 (MEN 2): Increased MTC risk History of pancreatitis: GLP-1 drugs may increase pancreatitis risk Type 1 diabetes: Not studied
